NovaBay Pharmaceuticals Inc (NBY)

2.18
0.04 1.90
AMEX : Health Care
Prev Close 2.22
Open 2.22
Day Low/High 2.22 / 2.23
52 Wk Low/High 1.62 / 16.23
Volume 11.13K
Avg Volume 43.20K
Exchange AMEX
Shares Outstanding 9.15M
Market Cap 20.87M
EPS -6.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay Pharmaceuticals Appoints Todd Zavodnick To Its Board Of Directors

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® lid and lash hygiene product for the domestic eye care market, announces the appointment of...

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay Pharmaceuticals To Hold First Quarter 2016 Conference Call On May 12

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

Clinical Data Presented At ARVO Showing NovaBay's Avenova Reduces Bacteria On Ocular Skin Surface By More Than 90%

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Hygiene product for the domestic eye care market, announces the presentation...

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay Pharmaceuticals Announces Agreement For Nearly $12 Million In Two-Tranche Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has entered...

NovaBay Pharmaceuticals Announces Filing Of Annual Report On Form 10-K

NovaBay Pharmaceuticals Announces Filing Of Annual Report On Form 10-K

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) (the "Company") announces that the Company's audited consolidated financial statements for the fiscal year ended December 31, 2015, included in the Company's Annual...

NovaBay Pharmaceuticals To Present At 28th Annual ROTH Conference

NovaBay Pharmaceuticals To Present At 28th Annual ROTH Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announced that Chairman and...

NovaBay Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results

NovaBay Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical Company focusing on commercializing its prescription Avenova ® Lid and Lash Cleanser for the domestic eye care market, reports financial...

NovaBay Pharmaceuticals To Hold 2015 Fourth Quarter And Full Year Conference Call On March 3

NovaBay Pharmaceuticals To Hold 2015 Fourth Quarter And Full Year Conference Call On March 3

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it will report...

NovaBay Pharmaceuticals Announces $2.83 Million Private Placement

NovaBay Pharmaceuticals Announces $2.83 Million Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY) a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has entered into...

NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales To Exceed $1.5 Million

NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales To Exceed $1.5 Million

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces that U.

3 Biotech Stocks Under $10 to Trade for Big Breakouts

3 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering breakout trades.

NovaBay Pharmaceuticals Secures $3 Million Bridge Loan

NovaBay Pharmaceuticals Secures $3 Million Bridge Loan

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its Avenova ® Lid and Lash Cleanser for the domestic eye care market, announces that it has secured a...

NovaBay Declares Reverse Stock Split

NovaBay Declares Reverse Stock Split

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) ("NovaBay" or the "Company"), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market,...

NovaBay Pharmaceuticals Announces Restructuring To Focus On Avenova Commercialization And Reports Third Quarter Financial Results

NovaBay Pharmaceuticals Announces Restructuring To Focus On Avenova Commercialization And Reports Third Quarter Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces a corporate restructuring to focus on the commercialization of its prescription Avenova ® Lid and Lash Cleanser.

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 19

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 19

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it has...

New Study Shows Success Fighting Eye Mites

New Study Shows Success Fighting Eye Mites

Tiny eye mites cause serious eye problems for millions of Americans, but a new study being presented by Dr. Kathryn Najafi-Tagol at a major Ophthalmology meeting shows that those problems can be successfully managed with Avenova® eyelid cleanser from NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 16

NovaBay Pharmaceuticals Reschedules Third Quarter 2015 Conference Call To November 16

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it has...

NovaBay Pharmaceuticals To Hold Third Quarter 2015 Conference Call On November 13

NovaBay Pharmaceuticals To Hold Third Quarter 2015 Conference Call On November 13

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it...

NovaBay Pharmaceuticals Completes 34 Patient Phase 2B Clinical Study

NovaBay Pharmaceuticals Completes 34 Patient Phase 2B Clinical Study

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces plans to...

NovaBay Announces Pricing Of Public Offering Of Common Stock And Warrants

NovaBay Announces Pricing Of Public Offering Of Common Stock And Warrants

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced the...

NovaBay Announces Proposed Public Offering Of Common Stock And Warrants

NovaBay Announces Proposed Public Offering Of Common Stock And Warrants

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that...

NovaBay Pharmaceuticals Provides Update On Avenova Sales Growth, Reports Progress With Intelli-Case Test Market Launch And Product Pipeline Advancement

NovaBay Pharmaceuticals Provides Update On Avenova Sales Growth, Reports Progress With Intelli-Case Test Market Launch And Product Pipeline Advancement

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces that third quarter...

PBE Will Showcase NeutroPhase Skin And Wound Cleanser At The Upcoming SAWC Fall Conference In Las Vegas. (Photo: Business Wire)

PBE Will Showcase NeutroPhase Skin And Wound Cleanser At The Upcoming SAWC Fall Conference In Las Vegas. (Photo: Business Wire)

Principle Business Enterprises, Inc. announced today that the company will be exhibiting its breakthrough product, NeutroPhase ® at the Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV on September 26-28.

John Crew, MD And Ron Najafi, Ph.D. Receive NNFF's Lifetime Health-Science Achievement Award 2015

John Crew, MD And Ron Najafi, Ph.D. Receive NNFF's Lifetime Health-Science Achievement Award 2015

The award recognizes the pioneering work that has brought new hope to victims of flesh-eating disease and their families

Avenova™ With Neutrox (Photo: Business Wire)

Avenova™ With Neutrox (Photo: Business Wire)

ALPHAEON Corporation and NovaBay® Pharmaceuticals, Inc.

Avenova™ With Neutrox (Photo: Business Wire)

Avenova™ With Neutrox (Photo: Business Wire)

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the...

NovaBay Pharmaceuticals To Present At Rodman & Renshaw Global Investment Conference

NovaBay Pharmaceuticals To Present At Rodman & Renshaw Global Investment Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel topical non-antibiotic antimicrobial products for the global eye care market, announces that...

Avenova™ With Neutrox (Photo: Business Wire)

Avenova™ With Neutrox (Photo: Business Wire)

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that the...